Ursula A. Matulonis, MD, Highlights the Potential of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

In a discussion with CancerNetwork®, Ursula A. Matulonis, MD, describes the potential of mirvetuximab soravtansine (IMGN853) as a treatment for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

In an interview with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, discussed the potential future of mirvetuximab soravtansine (IMGN853) in patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

In particular, she mentioned that mirvetuximab soravtansine, which is being assessed in the phase 3 SORAYA trial (NCT04296890) could prove to be a valuable therapy option in a population of patients with limited and less effective treatment options.

Transcript:

This is a really first-in-class antibody-drug conjugate against FRα, and it would be one of the newest drugs since [the] bevacizumab [Avastin] approval [in 2014]. Our patients with platinum-resistant ovarian cancer do not have many options. The use of single-agent chemotherapy [produces] very low response rates of about 10% to 12%, so we need new agents. This definitely represents a new agent with significant anticancer activity, and also a very manageable toxicity profile.

Reference

Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.